摘要
目的:探讨重组人干扰素α-2a(商品名淑润栓)治疗宫颈高危型人乳头瘤病毒(hr-HPV)感染的临床疗效。方法:将306例宫颈hr-HPV感染者随机分为两组,治疗组用重组人干扰素栓α-2a阴道用药,对照组仅用生理盐水冲洗,检测6个月后hr-HPV有无转阴。结果:治疗组、对照组hr-HPV的转阴率分别为75.16%、13.73%,两组比较差异有统计学意义(P<0.01)。结论:重组人干扰素栓α-2a治疗宫颈hr-HPV感染局部用药简单方便,疗效肯定,耐受性好,安全性高。
Objective：To explore the therapeutic effect of recombinant human interferon α-2a in treatment of cervical high risk human papillomavirus（HPV） infection.Methods：306 cases with cervical high risk HPV infection were divided into two groups randomly,the cases in treatment group were treated with recombinant human interferon α-2a by vaginal administration,the cases in control group were treated with normal saline by vaginal flushing,the negative conversion rates of high risk HPV after 6 months in the two groups were detected.Results：The negative conversion rates of high risk HPV in treatment group and control group were 75.16% and 13.73%,respectively,there was significant difference between the two groups（P〈0.01）.Conclusion：Recombinant human interferon α-2a is simple,convenient,effective,tolerant and safe in treatment of cervical high risk HPV infection.
出处
《中国妇幼保健》
CAS
北大核心
2011年第4期617-618,共2页
Maternal and Child Health Care of China
关键词
重组人干扰素
高危型人乳头瘤病毒
疗效观察
Recombinant human interferon
High risk human papillomavirus
Observation on therapeutic effect
